Nilotinib better than imatinib, dasatinib for CML in ColombiaChronic-myeloid-leukaemiatreatmentingentaconnectPharmacoeconomics & Outcomes News
Khay SathyaChoi Jeong HeuiKim In KyungKim Bo MeeA. M. Abd El-AtyShim Jae HanNature Clinical Practice OncologyDasatinib and nilotinib: effective alternatives to imatinib in CML and Ph-ALL?. Nature Clinical Practice Oncology 3 , 526-526 /...
dasatinib treatment cohorts and we analyze differences between the cohorts by fitting an established mathematical聽model of functional CML treatment to individual time courses. On average, dasatinib-treated patients show a steeper initial response, while the long-term response only marginally differed ...
Dasatinib: a once-daily option for imatinib-resistant CMLChronic-myeloid-leukaemia, treatmentDasatinib, therapeutic useImatinib, therapeutic useInpharma Weekly -doi:10.2165/00128413-200715730-00039NoneSpringer International PublishingInpharma Weekly
Progression-free survival at 24 months for imatinib-resistant patients was 75%.24 Thus, approximately half of patients with chronic phase CML with imatinib resistance or intolerance have significant and durable cytogenetic responses with dasatinib therapy. Further therapeutic considerations for nonresponders...
To evaluate the efficacy of bosutinib in patients with Ph+ CP CML according to subgroups of resistance (imatinib vs. dasatinib/nilotinib) or intolerance to prior tyrosine kinase inhibitors (TKIs). Design BYOND (NCT02228382) is an ongoing, phase 4, single-arm, open-label study. Data are report...
Imatinibwas among the first targetedanticancer agents, developed based on the understanding of the genomic basis ofchronic myeloid leukemia(CML) to specifically inhibit thetyrosine kinaseactivity of BCR–ABL. Althoughimatinibhas been proven to be a remarkably successful treatment for CML, nonresponse or...
Hydrea is used for chronic myelogenous leukemia, head and neck cancer Reviews & ratings 7.2 / 10 8 Reviews View more Dasatinib Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ... Reviews & ratings 7.7 / 10 27 Reviews View more Lenalidomide...
Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia 2010; 24: 855–857. Article CAS PubMed Google Scholar Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P et al. Dasatinib cellular uptake and efflux in chronic ...
The authors conclude that rescuing PP2A tumor suppressor activity could be of great therapeutic relevance in patients with advanced-phase ALL or CML who are unresponsive to imatinib and/or dasatinib.doi:10.1038/ncponc0987NoneNATURE CLINICAL PRACTICE ONCOLOGY...